Kingsview Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Kingsview Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,314	Closed	-$50.4K	–	1407
2025 Q4	$50.4K	Sell	12,314 -20,264	-62%	-$100K	﹤0.01%	1224
2025 Q3	$159K	Sell	32,578 -70,060	-68%	-$368K	﹤0.01%	1159
2025 Q2	$519K	Buy	102,638 +85,598	+502%	+$421K	0.01%	756
2025 Q1	$90.1K	Sell	17,040 -680	-4%	-$4.96K	﹤0.01%	1067
2024 Q4	$120K	Sell	17,720 -4,820	-21%	-$32.4K	﹤0.01%	1075
2024 Q3	$149K	Sell	22,540 -671	-3%	-$4.81K	﹤0.01%	1055
2024 Q2	$174K	Sell	23,211 -820	-3%	-$7.15K	﹤0.01%	1001
2024 Q1	$240K	Buy	+24,031	New	+$268K	0.01%	904

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kingsview Wealth Management's RXRX Position: Q1 2026 in Review

Kingsview Wealth Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 12,314 shares — an estimated $50.4K sold.

Kingsview Wealth Management first reported a position in RXRX in Q1 2024 and held it in 8 quarters. The position peaked at $519K in Q2 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Kingsview Wealth Management reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Kingsview Wealth Management sold 12,314 Recursion Pharmaceuticals shares in Q1 2026, an estimated $50.4K.
Kingsview Wealth Management first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 8 quarters.
Kingsview Wealth Management's Recursion Pharmaceuticals position peaked at $519K in Q2 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Kingsview Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.